ASTRAZENECA PLC Form 6-K November 06, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of November 2014

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.							
	Form 20-F X	Form 40-F					

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

ASTRAZENECA DEVELOPMENT PIPELINE, 30 SEPTEMBER 2014

Phase III / Pivotal / Registration

NMEs and significant additional indications

Submission dates shown for assets in Phase III and beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compound	Mechanism	Area Under	Date Commenced	HC	Estimate		China
-		Investigation	Phase	US	EU	Japan	China
Cardiovascular an							
Brilinta/ Brilique1		arterial thrombosis		Launched	Launched	Filed	Launched
Enonove#	antagonist omega-3 free	hyportrialyzaridaamia		Annrowad			
Epanova#	fatty acids	hypertriglyceridaemia		Approved			
Farxiga / Forxiga	•	Type 2 diabetes		Launched	Launched	Launched	Filed
8 8	inhibitor	71					
Myalept	leptin	lipodystrophy		Launched	2015	N/A	
	analogue						
roxadustat#	hypoxia-	anaemia in CKD /	Q3 2014	2018	N/A	N/A	2016
	inducible	ESRD					
	factor inhibitor						
Oncology	illiloitoi						
AZD9291	EGFR	advanced EGFRm	Q2 2014	2015	2015	2015	2017
	tyrosine	T790M NSCLC					
	kinase						
	inhibitor						
Caprelsa	VEGFR /	medullary thyroid		Launched	Launched	Q4 2014	Filed
	EGFR	cancer					
	tyrosine kinase						
	inhibitor with						
	RET kinase						
	activity						
MEDI4736#	anti-PD-L1	stage III NSCLC	Q2 2014	2017	2020	2020	
PACIFIC	MAb						
MEDI4736#	anti-PD-L1	3rd line NSCLC	Q1 2014	2016	2017	2017	
ATLANTIC¶	MAb	haime and lawles and	02 2012	2010	2010		
moxetumomab pasudotox#	anti-CD22 recombinant	hairy cell leukaemia	Q2 2013	2018	2018		
pasudotox#	immunotoxin						
Lynparza	PARP	BRCAm PSR ovarian		Filed	Filed7#		
(olaparib)	inhibitor	cancer					
Lynparza	PARP	1st line BRCAm	Q3 2013	2017	2017	2017	2018
(olaparib)SOLO-1		ovarian cancer					
Lynparza	PARP	BRCAm PSR ovarian	Q3 2013	2016	2016	2016	2016
(olaparib) SOLO-2		cancer	02 2012			2017	2010
Lynparza (olaparib) GOLD	PARP inhibitor	2nd line gastric cancer	Q3 2013			2017	2018
(otaparto) GOLD	mmonoi	Cancel					

Lynparza (olaparib)	PARP inhibitor	adjuvant breast cancer	Q2 2014	2020	2020	2020	2021
OlympiA							
Lynparza	PARP	metastatic breast	Q2 2014	2016	2016	2016	
(olaparib)	inhibitor	cancer					
OlympiAD							
selumetinib#	MEK	2nd line KRAS+	Q4 2013	2017	2017		
SELECT-1	inhibitor	NSCLC					
selumetinib#	MEK	differentiated thyroid	Q3 2013	2017	2017		
ASTRA	inhibitor	cancer					
selumetinib#	MEK	uveal melanoma	Q2 2014	2015	2015		
SUMIT	inhibitor						
tremelimumab¶	anti-CTLA-4	mesothelioma	Q2 2014	2016	2016	2016	
	MAb						

Phase III / Pivotal / Registration (continued)

		Area Under			Estimated Filing		
Compound	Mechanism	Investigation	Commenced Phase	US	EU	Japan	China
Respiratory, Inflammati	on and Autoimmun	ity					
benralizumab#	anti-IL-5R MAb	severe asthma	Q4 2013	2016	2016		
CALIMA, SIROCCO,							
ZONDA							
benralizumab#	anti-IL-5R MAb	COPD	Q3 20144	2018	2018		
TERRANOVA,							
GALATHEA							
brodalumab#	anti-IL-17R MAb	psoriasis	Q3 2012	++	++		
AMAGINE-1,2,3							
brodalumab#	anti-IL-17R MAb	•	Q1 2014	++	++		
AMVISION-1,2		arthritis	0.4.004.4	0.4.004.4	0.4.004.4		
Lesinurad3	selective uric	chronic	Q4 2011	Q4 2014	Q4 2014		
CLEAR 1,2		treatment of					
CRYSTAL	inhibitor (SURI)	patients with					
PT003 GFF	I AMA /I ADA	gout COPD	02 2012	2015	2016	2017	2017
PT003 GFF PT001 GP	LAMA / LABA		Q2 2013	2015 2016	2016 2016	2017 2017	2017
tralokinumab	LAMA anti-IL-13 MAb	COPD	Q2 2013 Q3 2014	2018	2018	2017	2017
STRATOS 1-2	anu-IL-13 MAD	severe asthma	Q3 2014	2018	2018	2018	
TROPOS							
Infection							
CAZ AVI#4	cephalosporin /	serious	Q1 2012	N/A	2015		2016
RECLAIM	• •	infections	Q1 2012	IV/A	2013		2010
RECEI IIIVI	inhibitor	micetions					
CAZ AVI#4	cephalosporin /		Q2 2013	N/A	2017		2018
REPROVE	• •	hospital-acquired	Q2 2013	1 1/11	2017		2010
NET NO VE	inhibitor	pneumonia / ventilator-					
		associated					

Zinforo#	extended		umonia umonia /		N/A	Launched	N/A	Filed
	1	skin	infections					
	cephalosporin							
	with affinity to							
	penicillin-binding							
	proteins							
Neuroscience								
Movantik/Moventig5#	oral peripherally-	opio	oid-induced	A	Approved	Filed6		
	acting mu-opioid	con	stipation					
	receptor							
	antagonist							

- # Partnered product.
- ¶ Registrational Phase II / III study.
- ++ Filing is the responsibility of the partner.
- 1 Brilinta in the US; Brilique in rest of world.
- 2 Farxiga in the US; Forxiga in rest of world.
- 3 Regulatory approval no longer being sought in China. This market will be served by RDEA3170.
- 4 No current plan to launch CAZ AVI in Japan.
- 5 Movantik in the US; Moventig in EU.
- 6 Positive opinion received.
- 7 Positive opinion announced on 24 October 2014.

Phases I and II

NMEs and significant additional indications

		Area Under		Date		Estimated	l Filing	
Compound	Mechanism	Investigation	Phase	Commenced Phase	US	EU	Japan	China
Cardiovascular	r and Metabolisn	n						
tenapanor	NHE3 inhibite	or ESRD-Pi/	II	Q1 2013				
(AZD1722)#		CKD with						
		T2DM1						
AZD4901	hormone	polycystic	II	Q2 2013				
	modulator	ovarian						
A 77D 1070	1 .	syndrome	-	02 201 4				
AZD1979	melanin-	obesity	Ι	Q2 2014				
	concentrating hormone							
	(MCH)							
	receptor							
MEDI6012	LCAT	ACS	I	Q1 2012				
MEDI8111	Rh-factor II	trauma /	I	Q1 2014				
		bleeding						
Oncology								
AZD1775#	WEE-1	ovarian	II	Q4 2012				
	inhibitor	cancer						
AZD2014		solid tumours	II	Q1 2013				

	mTOR serine /			
	threonine			
	kinase inhibitor			
AZD4547	FGFR tyrosine kinase inhibitor		II	Q4 2011
MEDI-551#	anti-CD19 MAb	CLL / DLBCL	II	Q1 2012
MEDI-573#	anti-IGF MAb	metastatic breast cancer	II	Q2 2012
Lynparza (olaparib)	PARP inhibitor		II	Q3 2014
selumetinib#	MEK inhibitor		II	Q1 2013
		NSCLC		
AZD5363#	AKT kinase inhibitor	breast cancer	II	Q1 2014
MEDI4736#	anti-PD-L1 MAb	solid tumours	II	Q3 2014
moxetumomab	anti-CD22	pALL	II	Q3 2014
pasudotox#	recombinant	p: 122		Q0 2 01.
1	immunotoxin			
volitinib#	MET tyrosine kinase inhibitor	papillary renal cell	II	Q2 2014
		carcinoma		
AZD5312#	androgen	solid tumours	I	Q2 2014
	receptor			
	inhibitor			
AZD6738	ATR serine /	solid tumours	I	Q4 2013
	threonine			
	kinase inhibitor			
AZD8186	PI3 kinase beta	solid tumours	I	Q2 2013
. 555 04 50 11	inhibitor			01.0010
AZD9150#	STAT3	haematological	I	Q1 2012
4. FD 0201	inhibitor	malignancies		02 2014
AZD9291 +	EGFR tyrosine		I	Q3 2014
(MEDI4736#	kinase inhibitor			
or selumetinib# or volitinib#)	+ (anti-PD-L1 or MEK	NSCLC		
or volitinib#)	inhibitor or			
	MET tyrosine			
	kinase			
	inhibitor)			
	111110101)			

Phases I and II (continued)

	Mechanism	Area Under Investigation Phase		Date	Estimated Filing			
Compound			Commenced Phase	US	EU	Japan	China	
Oncology (conti	nued)							
		NSCLC	I	Q3 2014				

MEDI4736#	anti-PD-L1			
after (AZD9291				
or Iressa or	+ (EGFR			
	tyrosine kinase			
+docetaxel) or	inhibitor or			
,	MEK inhibitor			
TATTON	or anti-			
MEDI CCCII	CTLA-4 MAb)	11.1.	τ.	01.2011
MEDI-565#	anti-CEA	solid tumours	I	Q1 2011
MEDI0620#	BiTE MAb	solid tumours	I	02 2012
MEDI0639#	anti-DLL-4 MAb	sond tulliours	1	Q2 2012
MEDI0680	anti-PD-1	solid tumours	I	Q4 2013
MEDIOOOU	MAb	sonu tuniours	1	Q4 2013
MEDI3617#	anti-ANG-2	solid tumours	I	Q4 2010
WILDISOT /#	MAb	sond tuniours	1	Q 4 2010
MEDI4736#	anti-PD-L1	various cancers	I	Q3 2014
WIEDITTON	MAb	various cancers	•	Q3 2011
MEDI4736# +	anti-PD-L1	solid tumours	I	Q2 2014
MEDI0680	MAb +		-	Q= = 01.
	anti-PD- 1 MAb			
MEDI4736# +	anti-PD-L1	solid tumours	I	Q3 2014
MEDI6469	MAb + murine			
	OX40 agonist			
MEDI4736# +	anti-PD-L1	melanoma	I	Q1 2014
dabrafenib +	MAb + BRAF			
trametinib2	inhibitor +			
	MEK inhibitor			
MEDI4736# +	anti-PD-L1	NSCLC	I	Q2 2014
Iressa	MAb + EGFR			
	tyrosine kinase			
	inhibitor			0.4.004.0
MEDI4736# +	anti-PD-L1	solid tumors	I	Q4 2013
tremelimumab				
MEDI 551# .	CTLA-4 MAb	1	т	02 2014
MEDI-551# + rituximab3	anti-CD19 MAb +	haematological malignancies	Ι	Q2 2014
Huxiiiaus	anti-CD20	manghancies		
	MAb			
MEDI6383	OX40 agonist	solid tumours	I	Q3 2014
MEDI6469#	murine OX40	solid tumours	Ī	Q1 2006
WIEDIO 10711	agonist	sona tamours	•	Q1 2000
Respiratory, Inf	lammation and Au	utoimmunity		
AZD2115#	MABA	COPD	II	Q2 2012
AZD9412#	inhaled	asthma / COPD	II	Q1 2010
	interferon			
anifrolumab#	anti-IFN-	SLE	II	Q1 2012
	alphaR MAb			•
brodalumab#	anti-IL-17R	asthma	II	Q2 2013
	MAb			
mavrilimumab#			II	Q1 2010

	anti-GM-CSFR	rheumatoid		
	MAb	arthritis		
MEDI2070#	anti-IL-23	Crohn's disease	II	Q1 2013
	MAb			
MEDI7183#	anti-a4b7 MAb	Crohn's disease	II	Q4 2012
	,	ulcerative		
	•	colitis		
MEDI9929#	anti-TSLP	asthma	II	Q2 2014
	MAb			
PT010	LAMA /	COPD	II	Q2 2014
	LABA / ICS			
RDEA3170	selective uric	chronic	II	Q3 2013
	acid	management of		
	reabsorption	hyperuricaemia		
	inhibitor	in patients with		
	(SURI)	gout		
sifalimumab#	anti-IFN-alpha	SLE	II	Q3 2008
	MAb			
tralokinumab	anti-IL-13	IPF	II	Q4 2012
	MAb			

Phases I and II (continued)

		Area Under		Date		Estimat	ed Filing	
Compound	Mechanism	Investigation	Phase	Commenced Phase	US	EU	Japan	China
Respiratory,	Inflammation and A	Autoimmunity (cor	tinued)					
AZD1419#	TLR9 agonist	asthma	I	Q3 2013				
AZD7594	inhaled SGRM	asthma / COPD	I	Q3 20124				
AZD7624	inhaled P38 inhibitor	COPD	I	Q1 2013				
MEDI-551#	anti-CD19 MAb	multiple sclerosis	Ι	Q3 2012				
MEDI4920	anti-CD40L- Tn3	primary	I	Q2 2014				
	fusion protein	Sjögren's syndrome						
MEDI5872#	anti-B7RP1	SLE	I	Q4 2008				
	MAb							
Infection								
AZD5847	oxazolidinone anti-bacterial	tuberculosis	II	Q4 2012				
	inhibitor							
CXL#	beta lactamase	MRSA	II	Q4 2010				
	inhibitor /			_				
	cephalosporin							
ATM AVI	monobactam /	targeted serious	I	Q4 2012				
	beta lactamase	bacterial						
	inhibitor	infections						
AZD0914	GyrAR		I	Q4 2013				

		serious		
		bacterial		
		infections		
MEDI-550	pandemic	pandemic	I	Q2 2006
	influenza virus	influenza		
	vaccine	prophylaxis		
MEDI-559	paediatric RSV	RSV	I	Q4 2008
	vaccine	prophylaxis		
MEDI4893	MAb binding to	hospital-acquired	I	Q1 2013
	S. aureus toxin	pneumonia /		
		serious S.		
		aureus infection		
MEDI3902	anti-Psl/PcrV	pseudomonas	I	Q3 2014
MEDI7510	RSV sF+GLA-	prevention of	I	Q2 2014
	SE	RSV disease in		
		older adults		
MEDI8897#	anti-RSV MAb-	passive RSV	I	Q2 2014
	YTE	prophylaxis		
Neuroscience				
AZD3241	myeloperoxidase	multiple system	II	Q2 2012
	inhibitor	atrophy5		
AZD5213	histamine-3	Tourette's	II	Q4 2013
	receptor	syndrome /		
	antagonist	neuropathic		
		pain	_	0.4.004.0
AZD3293#	beta-secretase	Alzheimer's	I	Q4 2012
1 FD (100	inhibitor	disease	-	02 2012
AZD6423	NMDA	suicidal	I	Q3 2013
MEDITOTA	antagonist	ideation		02 2014
MEDI1814	anti-amyloid	Alzheimer's	I	Q2 2014
	beta MAb	disease		

- # Partnered product.
- 1 Fluid retention indication for tenapanor terminated in Q2.
- 2 MedImmune-sponsored study in collaboration with GSK.
- 3 MedImmune-sponsored study in collaboration with Genentech.
- 4 Original programme terminated in 2013. Programme now reinitiated.
- 5 Multiple system atrophy is now the lead indication for this molecule.

Line Extensions

		Area Under	Date	Estimated Filing			
Compound	Mechanism	Investigation	Commenced Phase	US	EU	Japan	China
Cardiovascul	ar and Metaboli	sm					
Brilinta /	ADP	outcomes study in	Q4 2012	2017	2017	2017	2018
Brilique1	receptor	patients with					
EUCLID	antagonist	peripheral artery					
		disease					

Brilinta / Brilique1 PEGASUS- TIMI 54	ADP receptor antagonist	outcomes study in patients with prior myocardial infarction	Q4 2010	2015	2015	2015	2017
Brilinta / Brilique1 SOCRATES	ADP receptor antagonist	outcomes study in patients with stroke or TIA	Q1 2014	2016	2016	2016	2017
Brilinta / Brilique1 THEMIS	ADP receptor antagonist	outcomes study in patients with type 2 diabetes and CAD, but without a previous history of MI or stroke	Q1 2014	2017	2017	2018	2018
Bydureon Dual Chamber Pen	GLP-1 receptor agonist	type 2 diabetes		Launched	Approved	Filed	
Bydureon EXSCEL	GLP-1 receptor agonist	type 2 diabetes outcomes study	Q2 2010	2018	2018	2018	
Bydureon weekly suspension	GLP-1 receptor agonist	type 2 diabetes	Q1 2013	2015	2015		
Farxiga / Forxiga2 DECLARE- TIMI 58	SGLT-2 inhibitor	type 2 diabetes outcomes study	Q2 2013	2020	2020		
Kombiglyze	DPP-4	type 2 diabetes		Launched	Launched		Filed
XR FDC / Komboglyze FDC3	inhibitor / metformin FDC						
Komboglyze FDC3 Onglyza SAVOR- TIM	metformin FDC DPP-4	type 2 diabetes outcomes study	Q2 2010	Filed	Launched		2015
Komboglyze FDC3 Onglyza	metformin FDC DPP-4 Iinhibitor DPP-4 inhibitor / SGLT-2 inhibitor	• •	Q2 2010 Q2 2012	Filed 2015	Launched 2015		2015
Komboglyze FDC3 Onglyza SAVOR- TIM 53 saxagliptin / dapagliflozin	metformin FDC DPP-4 Iinhibitor DPP-4 inhibitor / SGLT-2 inhibitor FDC SGLT-2	outcomes study					2015

Faslodex FALCON	oestrogen receptor antagonist	1st line hormone receptor +ve advanced breast	Q4 2012	2016	2016	2016	2016
	-	cancer					
Respiratory,	Inflammation a	nd Autoimmunity					
Symbicort5	ICS / LABA	Breath Actuated					
		Inhaler asthma /					
		COPD					

Line Extensions (continued)

		Area Under	Date		Estimate	d Filing	
Compound	Mechanism	Investigation	Commenced Phase	US	EU	Japan	China
Neuroscience	e						
Diprivan#	sedative and anaesthetic	conscious sedation		N/A	Launched	Q4 2014	Launched
Gastrointesti	nal						
Entocort	glucocorticoid	Crohn's		Launched	Launched	2015	N/A
	steroid	disease /					
		ulcerative					
		colitis					
linaclotide#	GC-C receptor			N/A	N/A	N/A	2015
	peptide agonist	•	1				
		constipation					
		(IBS-C)		27/4	37/4	0.4.201.4	27/4
Nexium	proton pump	refractory		N/A	N/A	Q4 2014	N/A
	inhibitor	reflux					
NT .		esophagitis		NT/A	NT/A	NT/A	2017
Nexium	proton pump	stress ulcer		N/A	N/A	N/A	2017
NT .	inhibitor	prophylaxis		T 1 1	т 1 1	2016	TDD
Nexium	proton pump	paediatrics		Launched	Launched	2016	TBD
	inhibitor						

Partnered product.

- 1 Brilinta in the US; Brilique in rest of world.
- 2 Farxiga in the US; Forxiga in rest of world.
- 3 Kombiglyze XR in the US; Komboglyze FDC in the EU.
- 4 Xigduo XR FDC in the US; Xigduo FDC in the EU.
- 5 Development of a new BAI device is ongoing.
- 6 Approval announced on 30 October 2014.

Completed projects

		Area Under	Date		Estimated	Filing	
Compound	Mechanism	Investigation	Commenced Phase	US	EU	Japan	China
Nexium	proton pump inhibitor	peptic ulcer bleeding		Launched	Launched	N/A	Launched

Terminations (discontinued projects between 1 July and 30 September 2014)1

NME / Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NME	AZD1208	Safety / efficacy	haematological malignancies
NME	AZD8848#	Safety / efficacy	asthma
LCM	Iressa IMPRESS	Safety / efficacy	treatment beyond progression

Partnered product.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 06 November 2014 By: /s/ Adrian Kemp

Name: Adrian Kemp Title: Company Secretary

¹ tremelimumab+Iressa removed from table Q3 2014. Project is not terminated but is an investigator-sponsored study and, therefore, does not meet the requirement for inclusion in this table.